Kenvue Share Price Jumps 18% on Merger Deal with Kimberly-Clark
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Kenvue Inc. (NYSE: KVUE), known in Korean as 케뷰, is a Delaware-incorporated consumer health company headquartered in Summit, New Jersey. It was spun off from Johnson & Johnson in May 2023 and owns over-the-counter and personal care brands, including Tylenol, Neutrogena, Listerine, and Aveeno.
Corporate Structure
Kenvue employs approximately 22,200 people as of 2022 across research, manufacturing, and commercial operations. The company’s global headquarters is set to relocate from the Skillman section of Montgomery Township, New Jersey, to Summit. Its business is organized into three core segments:
- Self-Care: Over-the-counter medicines and natural health solutions
- Skin Health & Beauty: Science-based products in collaboration with dermatology experts
- Essential Health: Baby care, wound care, oral care, and women’s health
Kenvue Merger by Jorge Mallo
Recent Developments and News
On November 3, 2025, Kenvue and Kimberly-Clark Corporation entered into a definitive merger agreement. Under the terms:
- Each Kenvue share will convert into 0.14625 shares of Kimberly-Clark common stock plus $3.50 in cash.
- The new shares will be traded on the Nasdaq Global Select Market.
- Approval is required from the shareholders of both Kenvue and Kimberly-Clark, and the transaction is expected to close in the second half of 2026.
On the same day, Kenvue filed a Form 425 prospectus and a Form 8-K current report with the SEC detailing the merger structure. Following this announcement, shares rose 18.09% to $16.97 on a trading volume of 5,463,427.
Financial and Strategic Aspects
Kenvue’s recent trading and trailing financial metrics (TTM) are summarized below:
| Metric | Value |
|---|---|
| Share Price (Nov 3, 2025) | $16.97 (+18.09%) |
| Volume | 5.46 M shares |
| Market Capitalization | $27.6 B |
| Revenue | $15.14 B |
| Net Income | $1.42 B |
| Diluted EPS | $0.75 |
| Trailing P/E | 19.16 |
| Dividend Yield | 5.78% |
| Price/Sales | 2.00 |
| Enterprise Value/EBITDA | 12.58 |
Strategically, the Kimberly-Clark merger aims to:
- Leverage Scale: Combine consumer health portfolios to enhance distribution and R&D synergies.
- Enhance Diversification: Broaden geographic reach and product mix across personal care and health segments.
- Provide Shareholder Value: Deliver cash and equity in a larger public company to Kenvue shareholders.
Key risks include the integration of corporate cultures and obtaining necessary regulatory and shareholder approvals.
Market Position and Industry Context
Kenvue is the world’s largest pure-play consumer health company by sales, generating approximately $15 billion in annual revenue. This positions it ahead of competitors such as Bayer Consumer Health and Reckitt. The company’s strong brand heritage, rooted in over 135 years of product innovation, positions it in a fragmented industry where brand equity is significant. Following its separation from Johnson & Johnson in July 2023, Kenvue was added to the S&P 500 Dividend Aristocrats index.
tl;dr
On November 3, 2025, Kenvue agreed to merge with Kimberly-Clark. Shareholders will receive 0.14625 shares of Kimberly-Clark stock plus $3.50 per Kenvue share. The transaction, subject to regulatory approvals, is expected to close in the second half of 2026. Kenvue shares increased by 18.09% to $16.97 following the announcement, reflecting market expectations regarding scale and synergy opportunities, although integration and regulatory risks remain.